- Home
- ORIC vs EVMN Comparison
ORIC vs EVMN Comparison
Compare ORIC & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORIC | EVMN |
|---|---|---|
| Founded | 2014 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 783.0M | 628.9M |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ORIC | EVMN |
|---|---|---|
| Price | $8.56 | $18.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 6 |
| Target Price | $19.73 | ★ $38.25 |
| AVG Volume (30 Days) | ★ 1.4M | 279.0K |
| Earning Date | 02-17-2026 | 02-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,000,000.00 |
| Revenue This Year | N/A | $89.43 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 160.00 |
| 52 Week Low | $3.90 | $13.89 |
| 52 Week High | $14.93 | $24.03 |
Technical Indicators
Market Signals| Indicator | ORIC | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 39.26 | N/A |
| Support Level | $7.84 | N/A |
| Resistance Level | $8.92 | N/A |
| Average True Range (ATR) | 0.38 | 0.00 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 67.28 | 0.00 |
Price Performance
Historical ComparisonAbout ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.